Also this week: Allbirds pivots, Spirit’s future hangs in the air, and the Iran war dampens luxury spending.
Ralph Highnam blames shareprice fall on enduring uncertainty, especially in the US.
The company has more than $2 billion in bank debt.
US approval of bladder cancer test sees results heading in the right direction.
NZ Algae Innovations investigates the viability of large-scale NZ production of Tahi Spirulina.
Long saga nears end with overwhelming vote in favour of scheme.
Shareholders register protest votes against directors up for re-election.
New Tower boss talks up potential after removing sizeable legacy risk.
No suitable acquisition targets for clothing group, AGM hears.
Hospitals are increasingly using pressurised airflow tech to treat low-oxygen Covid patients.